SensArs has been granted FDA Breakthrough Device Designation for SENSY

SensArs is proud to announce that on August 11, 2021, FDA granted  Breakthrough Device Designation for our SENSY System! This is a huge step towards SensArs’ mission of bringing relief to those suffering from chronic peripheral neuropathic pain and/or sensory loss and is indicated for persons over 18, providing sensory feedback for those with limb loss to improve prosthesis function

Through our novel implantable stimulator, SensArs’ innovative technology elicits natural sensations of touch and movement that have been shown to effectively treat chronic neuropathic pain and reduce movement disability due to sensory loss.